Can you say SCAM?
The depot meets the definition that Sunil agreed to: SUBDERMAL, CONTINUOUS SLOW RELEASE FOR 3 MONTHS OR MORE. .... hence REDUCED royalties.
Did Sunil tell you what the royalty will be REDUCED to?
headed home to PennyLand.
You've seen it before many times.
Go with the track record of failure.
Nothing has reached Phase 3 in over 34 years.
The same failed "technology" is being peddled, why would you expect anything different?
and then when the FDA insists on additional trials, a drop below .20.
Will Sunil shutter operations and delist again?
That's the only remaining question.
He'll collect his salary for another year and then close up shop in Dec 2014?
WoW! quest finally admits that the royalty will be reduced.
Definition of "competing product": any subdermal product that provides a continuous flow of medication for at least 3 months.
RB's Atrigel meets the definition.
If there is competition both Braeburn and Titan would take a hit under the original agreement.
Titan's royalty would be on lower sales, so they would receive less.
The decrease would be shared based on the allocation in the original agreement.
NOW, SUNIL AGREED TO A NEW ALLOCATION WHICH GIVES BRAEBURN A LARGER ALLOCATION OF THE DECREASED SALES AND TITAN SHAREHOLDERS WOULD GET A SMALLER SHARE OF THE ALREADY DECREASED SALES.
Why shouldn't Titan and Braeburn take a hit based on the original agreed allocation?